Caring for HCT survivors: A review of the 2012 Guidelines to monitor late effects

Program Description

Join Dr. Navneet Majhail as he reviews key updates from the 2012 publication, Recommended screening and preventive practices for long-term survivors after HCT¹. This 45-minute webinar will help you understand the updated guidelines for long term follow-up care of HCT survivors, provide ideas for implementing these guidelines into your practice, and review free resources to help you share these recommendations.

Faculty

Navneet Majhail, M.D., M.S.
Medical Director, Health Services Research
National Marrow Donor Program

Learning Objectives

Identify the unique pre-, peri- and post-transplant exposures and risk factors associated with late complications of transplant.
Perform appropriate screening, testing, and vaccinations based on new published guidelines for transplant recipients including additional recommendations for recipients based on individual exposures and risk factors.
Discuss the role of a multidisciplinary team including transplant centers, primary care physicians and other health care providers in the follow-up care of transplant survivors.

Target Audience

This activity is intended for transplant physicians and staff who deliver care to patients following transplant.

Questions?

If you have any questions regarding this program, call Renee Ryan at (800) 526-7809 ext. 8430, or e-mail rryan@nmdp.org.

Reference

Majhail NS, Rizzo JD, Lee SJ, et al. Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation; Center for International Blood and Marrow Transplant Research (CIBMTR), American Society for Blood and Marrow Transplantation (ASBMT), European Group for Blood and Marrow Transplantation (EBMT), Asia-Pacific Blood and Marrow Transplantation Group (APBMT), Bone Marrow Transplant Society of Australia and New Zealand (BMTSANZ), East Mediterranean Blood and Marrow Transplantation Group (EMBMT) and Sociedade Brasileira de Transplante de Medula Ossea (SBTMO). Co-published in Biol Blood Marrow Transplant, 2012; 18(3): 348-371; Bone Marrow Transplant, 2012; 47(3): 337–341; and Hematol Oncol Stem Cell Ther, 2012; 5(1): 1-30.